Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed-dose combinations of LABA and ICS are the cornerstones of ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Enerzair (formerly QVM149) consists of long-acting beta agonist (LABA) indacaterol, long-acting muscarinic antagonist (LAMA) glycopyrronium, and inhaled corticosteroid (ICS) mometasone furoate ...

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...

StockNews.com downgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning. Separately, Scotiabank assumed ...

Introduction Despite advancements in asthma management, many patients continue to experience poor disease control, lung function decline, and frequent exacerbations. Clinical remission (CR) has been ...

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...

China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...

In many patients asthma control is difficult to achieve, even when LABA/ICS or LAMA/LABA/ICS combination are utilized. It is important to emphasize that even with biological treatment, based on a ...

It is a sliding-scale approach using a fixed dose of ICS+LABA twice a day plus supplementary doses to a ... or long-acting antimuscarinic agent (LAMA) can be added as a trial. There is no convincing ...